Retatrutide, the investigational triple hormone receptor agonist developed by Eli Lilly, has attracted significant public interest following promising Phase 2 trial data — but it remains unlicensed in the UK. With no MHRA or EMA approval, retatrutide cannot be legally prescribed or dispensed through NHS or private pharmacy channels. Yet reports suggest some individuals are already seeking it through unofficial routes. This article explains how people are currently accessing retatrutide, the serious legal and safety risks involved, what UK regulatory bodies advise, and which approved weight management treatments are legitimately available right now.

What Is Retatrutide and Where Does It Currently Stand in the UK?

Retatrutide is an unlicensed investigational medicine in the UK; it has no MHRA or EMA approval, remains in Phase 3 trials, and cannot be legally prescribed or dispensed outside approved clinical research.

Retatrutide is an investigational weight-loss medicine developed by Eli Lilly. It is a triple hormone receptor agonist that simultaneously activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Preclinical and early clinical data suggest this triple mechanism may reduce appetite and support metabolic function, though direct head-to-head comparisons with approved agents in humans are not yet available, and claims of superior potency remain unproven at this stage.

As of the date of publication, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, nor has it been approved by the European Medicines Agency (EMA). It remains in clinical development, with Phase 3 trials ongoing. Phase 2 trial data published in the New England Journal of Medicine in 2023 demonstrated substantial weight reduction — up to approximately 24% of body weight over 48 weeks — which generated considerable public and media interest.

Because retatrutide is not licensed in the UK, it cannot be legally prescribed, dispensed, or sold through standard NHS or private pharmacy channels. It is not listed in the British National Formulary (BNF), and NICE has not issued any guidance on its use. The UK does operate regulated frameworks for pre-authorisation access to medicines — including the Early Access to Medicines Scheme (EAMS) and named-patient unlicensed supply — however, neither of these routes is currently applicable to retatrutide. Any access outside of formally approved clinical trials therefore has no sanctioned UK pathway and carries important implications for patient safety.

How People Are Accessing Retatrutide at Present

People are obtaining retatrutide through unregulated overseas websites, compounding pharmacies abroad, and social media networks; clinical trial participation remains the only lawful, medically supervised route in the UK.

Despite its unapproved status, there are reports that some individuals are actively seeking and obtaining retatrutide through unofficial channels. Understanding how this is happening is important for both patients and clinicians.

The routes through which people are reportedly accessing retatrutide include:

• Online grey-market suppliers and overseas websites: A number of websites, often based outside the UK or EU, are selling retatrutide — sometimes labelled as a 'research chemical' — directly to consumers. These products are not subject to MHRA oversight and their quality, purity, and dosage accuracy cannot be verified. The MHRA has previously issued warnings about falsified and unauthorised injectable weight-loss products circulating in the UK market.

• Compounding pharmacies abroad: Some individuals are ordering from countries where regulatory frameworks differ. Compounded versions of retatrutide are not authorised anywhere and cannot be assumed to match the formulation used in clinical trials; their safety and quality are unverifiable.

• Participation in clinical trials: The only lawful and medically supervised route to accessing retatrutide in the UK is through enrolment in an approved clinical trial. UK-based trials can be found via the NIHR's Be Part of Research platform (bepartofresearch.nihr.ac.uk), the ISRCTN registry (isrctn.com), and ClinicalTrials.gov for multinational studies. Eligibility criteria typically include specific BMI thresholds and health conditions.

• Social media and peer networks: Online communities focused on weight loss have become informal information-sharing hubs, with some members directing others towards unregulated suppliers.

Clinical trial participation is the only lawful and medically supervised means of accessing retatrutide in the UK at present. All other routes described above carry significant legal and health risks. Unauthorised supply of prescription medicines is illegal under the Human Medicines Regulations 2012, and importing unlicensed medicines for personal use may also contravene UK law.

The Risks of Obtaining Retatrutide Outside Clinical Trials

Sourcing retatrutide outside clinical trials risks counterfeit or contaminated products, an incompletely established adverse effect profile, no medical oversight, and potential legal consequences under UK medicines law.

Obtaining any unlicensed medicine outside of a regulated clinical trial environment carries serious risks, and retatrutide is no exception.

Product quality and safety: Medicines purchased from unregulated online suppliers or grey-market sources may be counterfeit, contaminated, or incorrectly dosed. Without MHRA oversight, there is no guarantee that what is labelled as retatrutide contains the active compound — or that it does not contain harmful adulterants.

Incompletely established adverse effect profile: Although Phase 2 trial data (NEJM, 2023) provides some safety information, the full adverse effect profile of retatrutide has not yet been established through the complete Phase 3 programme. Side effects reported in trials include nausea, vomiting, diarrhoea, decreased appetite, and injection site reactions. Rarer or longer-term effects remain under investigation. Without medical supervision, adverse effects may go unrecognised or unmanaged.

No medical oversight: In a clinical trial, participants are closely monitored by healthcare professionals who can identify and respond to complications. Self-administering an unlicensed injectable medicine without this support significantly increases risk.

Legal implications: Unauthorised supply of prescription medicines is illegal in the UK. Importing unlicensed medicines for personal use may also contravene the Human Medicines Regulations 2012, and individuals should be aware of the potential legal consequences.

When to seek urgent help: If you experience any of the following after taking any unregulated product, seek urgent medical attention immediately — call 999 or go to your nearest A&E:

• Severe or persistent abdominal pain (which may indicate pancreatitis)

• Persistent vomiting or signs of dehydration (dizziness, very dark urine, inability to keep fluids down)

• Signs of a serious allergic reaction (swelling of the face, lips, or throat; difficulty breathing; rash)

For less urgent concerns, contact your GP or call NHS 111. You should also report any suspected side effects from an unregulated product via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

MHRA and NHS Guidance on Unapproved Weight Loss Medicines

The MHRA advises only using medicines prescribed by a registered UK clinician and dispensed by a GPhC-registered pharmacy; suspected unlicensed products should be reported via the MHRA Yellow Card scheme.

The MHRA has issued repeated warnings about the dangers of purchasing unlicensed weight-loss medicines online. These warnings are particularly relevant in the context of injectable GLP-1 and related receptor agonists, a class that has seen a significant rise in falsified and substandard products circulating in the UK.

The MHRA advises the public to:

• Only use medicines that have been prescribed by a registered UK clinician and dispensed by a pharmacy registered with the General Pharmaceutical Council (GPhC). You can verify whether an online pharmacy is legitimately registered using the GPhC online register at pharmacyregulation.org.

• Check the electronic Medicines Compendium (emc) at medicines.org.uk for UK-authorised product information, including Summaries of Product Characteristics (SmPCs) and Patient Information Leaflets, to confirm whether a medicine is licensed in the UK.

• Be cautious of websites that do not require a prescription, offer unusually low prices, or cannot be verified on the GPhC register.

• Report suspected counterfeit or unlicensed medicines to the MHRA via their 'report a problem with a medicine or medical device' page (mhra.gov.uk). Suspected adverse reactions to any medicine, including unlicensed products, should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

• Report suspected illegal sale of medicines directly to the MHRA using their online reporting tool.

The NHS does not endorse, fund, or support access to retatrutide outside of approved research settings. NHS England's guidance on obesity pharmacotherapy is aligned with NICE technology appraisals, which currently cover only licensed medicines. Clinicians working within the NHS are not in a position to prescribe or recommend retatrutide to patients. Patients are encouraged to raise questions about emerging treatments with their GP or specialist rather than seeking unregulated alternatives independently.

What Approved Alternatives Are Available in the UK Right Now?

MHRA-approved options for weight management in the UK include semaglutide 2.4 mg (Wegovy®), tirzepatide (Mounjaro®), orlistat, and naltrexone/bupropion (Mysimba®), with eligibility criteria varying by treatment.

For individuals seeking effective, evidence-based pharmacological support for weight management in the UK, there are currently several MHRA-approved options available, some of which are also recommended by NICE.

Semaglutide 2.4 mg (Wegovy®): A once-weekly injectable GLP-1 receptor agonist approved by the MHRA for chronic weight management. NICE recommended semaglutide 2.4 mg (TA875, 2023) for use within specialist Tier 3 weight management services in adults with a BMI of ≥35 kg/m² (or ≥32.5 kg/m² in people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background) with at least one weight-related comorbidity, or a BMI of 30–34.9 kg/m² in specific circumstances. NICE guidance specifies a maximum treatment duration of two years within the NHS. Access criteria and availability vary across NHS regions.

Tirzepatide (Mounjaro®): A dual GIP and GLP-1 receptor agonist approved by the MHRA for weight management in adults. NICE has recommended tirzepatide for obesity (TA1026, 2024) within specialist weight management services, subject to specific BMI and comorbidity criteria and a maximum treatment duration. Readers should refer to the current NICE technology appraisal and the emc SmPC for Mounjaro for the most up-to-date access criteria, as commissioning arrangements continue to evolve. Clinical trial data demonstrated weight reductions of up to approximately 22% of body weight.

Orlistat: An orally administered option that works by inhibiting pancreatic lipase, reducing dietary fat absorption by approximately 30%. It is available on NHS prescription for adults with a BMI ≥28 kg/m² (with risk factors) or ≥30 kg/m², alongside dietary and lifestyle measures. It is also available over the counter as Alli® (60 mg) for adults with a BMI ≥28 kg/m². Common side effects include oily or fatty stools and faecal urgency, particularly if dietary fat intake is high.

Naltrexone/bupropion (Mysimba®): A licensed combination oral tablet that acts on the central nervous system to reduce appetite and food cravings. It is available via private prescription in the UK but is not routinely commissioned on the NHS and is not NICE-recommended for routine NHS use. Important contraindications include uncontrolled hypertension, a history of seizure disorders, and current or recent use of opioid medicines. Patients should review the full SmPC on the emc before use.

Patients should discuss eligibility for these treatments with their GP or a specialist obesity service, as access criteria, commissioning arrangements, and availability vary across NHS regions.

How to Speak to a UK Clinician About Emerging Obesity Treatments

The safest first step is discussing emerging treatments with your GP or a specialist obesity service, who can assess eligibility for approved therapies and advise on legitimate clinical trial opportunities.

If you are interested in retatrutide or other emerging obesity treatments, the most appropriate and safest first step is to have an open, informed conversation with a registered UK healthcare professional. Clinicians are well placed to discuss the current evidence base, explain what is and is not yet available, and help you access appropriate care through legitimate channels.

Starting the conversation with your GP: Your GP can review your weight management history, assess your eligibility for currently approved treatments, and refer you to a specialist obesity service if appropriate. It is helpful to come prepared with questions and to be honest about any steps you may have already taken, including use of any unregulated products. GPs are bound by patient confidentiality and are there to support, not judge.

Specialist weight management services: NHS Tier 3 and Tier 4 obesity services provide multidisciplinary support including dietetic, psychological, and pharmacological input. These services are best placed to discuss emerging treatments and may have access to clinical trial opportunities. Waiting times and referral criteria vary by region.

Clinical trial participation: If you are interested in accessing retatrutide through a legitimate route, ask your clinician about ongoing trials. You can also search for UK-based studies via the NIHR Be Part of Research platform (bepartofresearch.nihr.ac.uk), the ISRCTN registry (isrctn.com), or ClinicalTrials.gov for multinational trials. Eligibility criteria will apply.

Private clinicians: Some private obesity specialists may be more up to date with emerging research and can provide detailed guidance on the pipeline of treatments. Ensure any private clinician is registered with the General Medical Council (GMC) (gmcuk.org) and that the provider is registered with the Care Quality Commission (CQC) (cqc.org.uk). Any medicines prescribed should be MHRA-approved.

Above all, patient safety must remain the priority. No potential benefit of an unapproved medicine outweighs the risks of accessing it through unregulated means.

Frequently Asked Questions